-
公开(公告)号：KR101352135B1
公开(公告)日：2014-01-16
申请号：KR1020110119197
申请日：2011-11-15
Applicant: 경북대학교 산학협력단 , 대한민국 (식품의약품안전처장)
Abstract: 본 발명은 시스플라틴으로 인해 유도된 간독성 진단용 바이오마커 조성물 및 이를 이용한 진단 방법에 관한 것으로서, 상기 바이오마커 조성물 및 진단방법을 통해, 시스플라틴이 간독성을 일으켰는지의 여부를 용이하게 확인할 수 있다. 시스플라틴은 항암효과가 탁월함에도 불구하고, 간독성이 유발될 수 있어 항암치료에 일부 제한이 있었던 약물이었기에, 상기 방법을 통해 시스플라틴으로 인해 일어나는 간독성을 조기에 진단하여 항암치료 및 간독성 억제를 효과적으로 할 수 있는 방법을 제공한다.
-
公开(公告)号：KR1020100041018A
公开(公告)日：2010-04-22
申请号：KR1020080099994
申请日：2008-10-13
Applicant: 대한민국 (식품의약품안전처장)
IPC: C12Q1/68
CPC classification number: G01N33/53 , C12Q1/6837 , C12Q2600/142
Abstract: PURPOSE: A method for determining food additive having hepatotoxicity is provided to effectively determine hepatotoxicity and develop safe food additive. CONSTITUTION: A method for determining food additive having hepatotoxicity comprises: a step of treating food additive to liver cell line and culturing; a step of isolating RNA from liver cell line and synthesizing cDNA; and a step of measuring hepatotoxicity-specific gene expression level and comparing with control liver cell line to determine presence of hepatotoxicity. The liver cell line is HepG2. The measurement is performed through Northern blot.
Abstract translation: 目的：提供一种确定具有肝毒性的食品添加剂的方法，以有效确定肝毒性并开发安全的食品添加剂。 构成：一种确定具有肝毒性的食品添加剂的方法，包括：对肝细胞系的食品添加剂进行处理和培养的步骤; 从肝细胞系中分离RNA并合成cDNA的步骤; 测定肝毒性特异性基因表达水平，与对照肝细胞系比较，测定肝毒性的存在。 肝细胞系为HepG2。 通过Northern印迹进行测量。
-
公开(公告)号：KR1020130053349A
公开(公告)日：2013-05-23
申请号：KR1020110119197
申请日：2011-11-15
Applicant: 경북대학교 산학협력단 , 대한민국 (식품의약품안전처장)
CPC classification number: G01N33/6893 , C12Q1/6837 , C12Q1/6886 , G01N33/5308
Abstract: PURPOSE: A biomarker composition and a diagnosis method using the same are provided to easily diagnose hepatotoxicity by cisplatin, to ensure excellent anticancer effect, and to ensure anticancer therapy and hepatotoxicity suppression. CONSTITUTION: A biomarker composition for diagnosing hepatotoxicity induced by cisplatin contains 3 or more kinds of proteins selected from the following: fructose 1,6-bisphosphatase 1 (FBP1, Accession No. IPI00231745); fatty acid synthase (FASN, Accession No. IPI00200661); catalase (CAT, Accession No. IPI00231742); peroxiredoxin-1 (PRDX1, Accession No. IPI00211779); 60kDa heat shock protein (HSPD1, Accession No. IPI00763910); malate dehydrogenase 2 (MDH2, Accession No. IPI00197696); arginase 1 (ARG1, Accession No. IPI00327518); tropomyosin 1 (TPM1, Accession No. IPI00210945); tropomyosin 3 (TPM3, Accession No. IPI00210941); and cathepsin B (CTSB, Accession No. IPI00212811). A diagnostic agent contains an antibody which recognizes three or more kinds of proteins.
Abstract translation: 目的：提供生物标志物组合物和使用其的诊断方法以容易地通过顺铂诊断肝毒性，以确保优异的抗癌作用，并确保抗癌治疗和肝毒性抑制。 构成：用于诊断顺铂诱导的肝毒性的生物标志物组合物含有3种或更多种选自以下的蛋白质：果糖1,6-二磷酸酶1（FBP1，登录号IPI00231745）; 脂肪酸合成酶（FASN，登录号IPI00200661）; 过氧化氢酶（CAT，登录号IPI00231742）; 过氧氧化还原酶1（PRDX1，登录号IPI00211779）; 60kDa热休克蛋白（HSPD1，登录号IPI00763910）; 苹果酸脱氢酶2（MDH2，登录号IPI00197696）; 精氨酸酶1（ARG1，登录号IPI00327518）; 原肌球蛋白1（TPM1，登录号IPI00210945）; 原肌球蛋白3（TPM3，登录号IPI00210941）; 和组织蛋白酶B（CTSB，登录号IPI00212811）。 诊断剂包含识别三种或更多种蛋白质的抗体。
-
公开(公告)号：KR1020100040138A
公开(公告)日：2010-04-19
申请号：KR1020080099228
申请日：2008-10-09
Applicant: 대한민국 (식품의약품안전처장)
IPC: C12Q1/68
CPC classification number: C12Q1/6837 , C12Q2600/142
Abstract: PURPOSE: A method for determining medicinal product having mytotoxicity is provided to effectively determine mytotoxicity and develop safe drug. CONSTITUTION: A method for determining medicinal product having mytotoxicity comprises: a step of treating medicinal product to muscular cells and culturing the cells; a step of isolating RNA form the cultured cells and synthesizing cRNA; and a step of measuring expression level of mytotoxicity-specific gene in the synthesized cRNA and comparing cRNA of untreated group. The expression level of the gene is performed through micorarray.
Abstract translation: 目的：提供一种确定具有肌肉毒性的药物的方法，以有效测定肌肉毒性并开发安全药物。 构成：用于测定具有肌肉毒性的药物的方法，其特征在于，包括：对肌肉细胞处理药物并培养细胞的步骤; 分离RNA形成培养细胞并合成cRNA的步骤; 并测定合成的cRNA中骨髓毒素特异性基因的表达水平，并比较未处理组的cRNA。 通过微阵列进行基因的表达水平。
-
-
-
Search Results
4
records
(took 0.043 seconds)
